Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,363,777
  • Shares Outstanding, K 76,527
  • Annual Sales, $ 720 K
  • Annual Income, $ -348,870 K
  • 60-Month Beta 2.09
  • Price/Sales 8,179.56
  • Price/Cash Flow N/A
  • Price/Book 2.33
Trade CRSP with:

Options Overview Details

View History
  • Implied Volatility 80.79%
  • Historical Volatility 49.30%
  • IV Percentile 85%
  • IV Rank 61.82%
  • IV High 99.59% on 02/01/21
  • IV Low 50.36% on 09/17/21
  • Put/Call Vol Ratio 2.31
  • Today's Volume 7,371
  • Volume Avg (30-Day) 4,721
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 86,961
  • Open Int (30-Day) 76,552

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -1.72
  • Number of Estimates 10
  • High Estimate -1.38
  • Low Estimate -1.88
  • Prior Year -1.50
  • Growth Rate Est. (year over year) -14.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.16 +2.83%
on 12/03/21
95.88 -26.90%
on 11/04/21
-26.79 (-27.65%)
since 11/03/21
3-Month
68.16 +2.83%
on 12/03/21
124.79 -43.83%
on 09/17/21
-51.87 (-42.53%)
since 09/03/21
52-Week
68.16 +2.83%
on 12/03/21
220.20 -68.17%
on 01/15/21
-70.37 (-50.10%)
since 12/03/20

Most Recent Stories

More News
CRISPR Therapeutics AG (CRSP) Down 17.4% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRSP : 70.09 (-8.80%)
Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II

Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.

VRTX : 203.81 (-0.31%)
SRPT : 78.50 (-5.64%)
CRSP : 70.09 (-8.80%)
ISEE : 14.10 (-5.11%)
CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

VRTX : 203.81 (-0.31%)
EDIT : 27.72 (-7.69%)
CRSP : 70.09 (-8.80%)
DTIL : 8.19 (-6.08%)
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...

CRSP : 70.09 (-8.80%)
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...

CRSP : 70.09 (-8.80%)
CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

VRTX : 203.81 (-0.31%)
CRSP : 70.09 (-8.80%)
SYBX : 2.27 (-4.22%)
DTIL : 8.19 (-6.08%)
CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

REGN : 635.16 (+0.18%)
ALKS : 22.04 (-0.32%)
VRTX : 203.81 (-0.31%)
CRSP : 70.09 (-8.80%)
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1.18% and -78.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

CRSP : 70.09 (-8.80%)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

-Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late...

CRSP : 70.09 (-8.80%)
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View

Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.

REGN : 635.16 (+0.18%)
ALKS : 22.04 (-0.32%)
VRTX : 203.81 (-0.31%)
CRSP : 70.09 (-8.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

3rd Resistance Point 83.93
2nd Resistance Point 80.39
1st Resistance Point 75.24
Last Price 70.09
1st Support Level 66.55
2nd Support Level 63.01
3rd Support Level 57.86

See More

52-Week High 220.20
Fibonacci 61.8% 162.12
Fibonacci 50% 144.18
Fibonacci 38.2% 126.24
Last Price 70.09
52-Week Low 68.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar